首页> 美国卫生研究院文献>International Journal of Fertility Sterility >Clomiphene Citrate Treatment Cycle Outcomes of PolycysticOvary Syndrome Patients Based on Basal High SensitiveC-Reactive Protein Levels: A Cross-Sectional Study
【2h】

Clomiphene Citrate Treatment Cycle Outcomes of PolycysticOvary Syndrome Patients Based on Basal High SensitiveC-Reactive Protein Levels: A Cross-Sectional Study

机译:多囊性枸酸克罗米芬治疗周期结果基于基础高敏感度的卵巢综合征患者C反应蛋白水平:跨领域研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

BackgroundPolycystic ovary syndrome (PCOS) is highly associated with an ovulatory infertility, features of the metabolic syndrome, including obesity, insulin resistance and dyslipidemia. Serum concentrations of high sensitive C-reactive protein (hs-CRP) were significantly higher in obese than in non-obese PCOS patients at baseline, suggesting a relationship between elevated hs-CRP levels and obesity. The aim of this study was to evaluate whether cycle day 3 hs-CRP levels before clomiphene citrate (CC) treatment would predict cycle outcomes in women with PCOS.
机译:背景多囊卵巢综合征(PCOS)与排卵性不孕症,代谢综合征的特征(包括肥胖症,胰岛素抵抗和血脂异常)高度相关。在基线时,肥胖人群中高敏C反应蛋白(hs-CRP)的血清浓度显着高于非肥胖PCOS患者,这表明hs-CRP水平升高与肥胖之间存在关联。这项研究的目的是评估柠檬酸克罗米芬(CC)治疗前第3天的hs-CRP水平是否可以预测PCOS妇女的周期结局。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号